To amend sections 3712.01, 3712.03, 3712.04, 3712.06, and 3712.062 and to enact sections 3712.20 and 3712.21 of the Revised Code regarding the regulation of hospice care programs.
HB945 revises Ohio’s hospice care licensing and oversight framework. It updates statutory definitions for hospice care programs, hospice patients, pediatric respite care programs, pediatric transition care programs, and related terms, while also clarifying the services that must be provided under a licensed hospice program. The bill would require the Department of Health to license hospice providers under a more detailed application process, including disclosure of ownership, administrators, medical directors, prior discipline, fraud-related history, and criminal background checks.
The bill also tightens operational requirements for hospice providers. It shortens the standard license term from three years to one year, requires a $100,000 surety bond, restricts ownership changes for five years after initial licensure, and authorizes suspension or revocation for a broader set of compliance and quality-related reasons. It adds new rules for home-based hospice programs to prevent diversion of opioid medications, including written disposal policies, patient/family education, monitoring, reporting to law enforcement, and penalties for noncompliance. The bill further limits how many hospice programs one person may oversee as chief administrator or medical director and directs the Department of Health to monitor CMS quality measures and use those metrics to trigger surveys.
In practical terms, the bill would significantly expand state regulatory control over hospice providers and increase the compliance burden on existing and prospective licensees. It would affect hospice care programs, their owners, administrators, medical directors, patients receiving home hospice services, and families handling controlled substances after a patient’s death. It also creates new enforcement tools for the Department of Health, including licensing delays, surveys, fines, and license suspensions tied to quality and opioid-diversion concerns.
Because the bill was only introduced and there are no recorded committee transcripts or votes, there is no documented public debate in the available materials. The overall sentiment cannot be measured from floor or committee action, but the structure of the bill suggests a policy focus on stronger oversight, fraud prevention, and patient safety rather than expansion of provider flexibility. The absence of recorded opposition or support in the available history means no formal sentiment can be inferred beyond the bill’s regulatory emphasis.
The main likely points of contention are the stricter licensing and ownership restrictions, the one-year license term, the surety bond requirement, and the limits on shared administrators and medical directors, which could be viewed as burdensome by providers—especially smaller or rural programs. At the same time, the opioid-diversion provisions and enhanced background checks appear aimed at consumer protection and accountability, which may draw support from regulators and patient-safety advocates. The bill also includes a rural-area exception for medical director limits, indicating an attempt to balance oversight with access concerns.
HB945 would amend Ohio Revised Code Chapter 3712 governing hospice care programs and add new sections imposing more detailed licensing, ownership, staffing, quality-monitoring, and opioid-diversion requirements. It would replace existing provisions with a more prescriptive regulatory scheme administered by the Department of Health, including new application disclosures, criminal records checks, surety bond requirements, license renewal conditions, and authority to suspend or revoke licenses for specified compliance and quality failures. It would also create new obligations for home hospice providers regarding controlled-substance disposal and reporting, and it would direct the department to monitor CMS quality measures and use them to trigger inspections.
The available record shows no committee testimony, recorded debate, or votes, so there is no documented partisan or stakeholder sentiment to summarize. Based on the bill text alone, the measure appears to reflect a generally cautious, enforcement-oriented approach to hospice regulation, emphasizing fraud prevention, quality oversight, and opioid control. That suggests likely support from regulators and patient-safety advocates, with possible concern from hospice operators about added administrative and financial burdens.
The most likely areas of contention are the bill’s tighter licensing regime, especially the one-year license term, $100,000 surety bond, five-year ownership-change restriction, and expanded grounds for denial or revocation. Hospice providers may also object to the limits on shared chief administrators and medical directors, the required reporting and disposal procedures for opioids, and the added survey and monitoring requirements. The bill partially addresses access concerns by allowing rural-area exemptions for the medical-director limit, suggesting that rural providers could be especially affected by the staffing restrictions.